The American Journal of Psychiatry
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via Google Scholar
Google Scholar
* Articles by FITZ-GERALD, M. J.
* Articles by CALHOUN, A.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by FITZ-GERALD, M. J.
* Articles by CALHOUN, A.
Related Collections
* Bipolar Disorder
* Other Neuroleptics
Am J Psychiatry 156:1114, July 1999
© 1999 American Psychiatric Association


Letter to the Editor

Olanzapine-Induced Mania

MARY JO FITZ-GERALD, M.D., HAROLD B. PINKOFSKY, M.D., PH.D., GUY BRANNON, M.D., EVELYN DANDRIDGE, R.N., and ANDREW CALHOUN, M.D.
Shreveport, La.

To the Editor: We present the following case of possible olanzapine-induced mania.

Mr. A, a 44-year-old man with a diagnosis of paranoid schizophrenia, had been seen at a mental health center for 19 years. An author (M.J.F.) had treated the patient for the past 8 years. A chart review revealed symptoms consisting of auditory and visual hallucinations, looseness of associations, and blunted affect. A careful review of his record did not reveal any history of manic symptoms.

Mr. A's medication consisted of a regimen of fluphenazine decanoate every 2 weeks and fluphenazine hydrochloride and diphenhydramine at night. A trial of olanzapine was initiated to control treatment-unresponsive hallucinations and to minimize the risk of exacerbating his tardive dyskinesia. His fluphenazine hydrochloride dose was discontinued, and the fluphenazine decanoate dose was reduced to every 3 weeks. One month later, he developed euphoria with frequent laughter, lessened sleep, and a higher sex drive. During a 5-day hospitalization, Mr. A's olanzapine dose was increased to 20 mg at bedtime, and he was started on a regimen of valproic acid and clonazepam. His serum valproic acid level on the day of his discharge was 95.3 µg/ml. Shortly after discharge, he was arrested for disturbing the peace. While in a correctional facility, he was under constant surveillance and continued to receive his medication. Two weeks after his discharge from the hospital, Mr. A was laughing continuously and uncontrollably. He could not answer questions or follow commands because of the laughter. The police reported that he did not sleep at all because of his laughter and exhibited almost continuous masturbatory activity for several days. A decision was made to taper and discontinue his dose of olanzapine. His fluphenazine decanoate, valproic acid, and clonazepam doses were increased. The correctional facility then reported that his sleep returned to normal and his laughter and masturbatory activity decreased. One week later, Mr. A returned to his usual state. His affect was blunted, and he experienced auditory hallucinations. His speech was not spontaneous, and he did not display loose associations. On follow-up examination, the manic symptoms had not returned.

Olanzapine is an atypical antipsychotic agent with high binding affinity for serotonin 5-HT2, dopamine D2, muscarinic, {alpha}-adrenergic, and histaminergic receptors. Its activity profile shows an effect on both positive and negative symptoms of schizophrenia (1). Antipsychotic agents are also used in the treatment of mania (2), and recent case reports suggest that olanzapine may be effective as well (3). A careful review of the literature shows only one other case of possible olanzapine-induced mania or hypomania (4). This additional case suggests that in some patients, olanzapine may precipitate mania.

REFERENCES

  1. Beasley CM, Tollefson GD, Tran PV: Efficacy of olanzapine: an overview of pivotal clinical trials. J Clin Psychiatry 1997; 58(suppl 10):7–12
  2. Shopsin B, Gershon S, Thompson H, Collins P: Psychoactive drugs in mania: a controlled comparison of lithium carbonate, chlorpromazine, and haloperidol. Arch Gen Psychiatry 1975; 32:34–42[Abstract/Free Full Text]
  3. Weisler RH, Ahearn EP, Davidson JR, Wallace CD: Adjunctive use of olanzapine in mood disorders: five case reports. Ann Clin Psychiatry 1997; 9:259–262[Medline]
  4. London JA: Mania associated with olanzapine. J Am Acad Child Adolesc Psychiatry 1998; 37:135–136



This article has been cited by other articles:


Home page
J PsychopharmacolHome page
A. Mishra, P. B. Moore, and R. Hobbs
Does Quetiapine Have Mood Altering Properties?
J Psychopharmacol, June 1, 2004; 18(2): 281 - 284.
[Abstract] [PDF]


Home page
Br. J. PsychiatryHome page
S. Fahy and T. J. Fahy
Induction of manic symptoms by novel antipsychotics
The British Journal of Psychiatry, June 1, 2000; 176 (6): 597 - 597.
[Full Text] [PDF]


This Article
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via Google Scholar
Google Scholar
* Articles by FITZ-GERALD, M. J.
* Articles by CALHOUN, A.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by FITZ-GERALD, M. J.
* Articles by CALHOUN, A.
Related Collections
* Bipolar Disorder
* Other Neuroleptics


Get information about faster international access.

Privacy Policy

Copyright © 1999 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org